Back to search results

A Study of Multiparametric Ultrasound Imaging for Pancreatic Cancer and Thyroid Nodules

This study is looking at how well a special type of ultrasound, called multiparametric ultrasound (mpUS) imaging, can examine and provide information about different tissues, both cancerous and non-cancerous. Researchers will compare mpUS imaging results to standard ultrasound and other tests. mpUS imaging combines different ultrasound methods to create a more detailed picture of tissue, showing things like blood vessels and detailed tissue structure, beyond what a standard ultrasound can show. You may be eligible if you are 18 or older and are at high risk for pancreatic cancer, already having standard endoscopic ultrasounds. The study aims to see if mpUS imaging is practical to use, with results measured after one day. This study is currently recruiting 85 participants.

Study design
This is an interventional study with an estimated enrollment of 85 participants. It is not specified if it is randomized or blinded.
What's involved
You will undergo added research sequences during your standard ultrasound scans, which will add about 15 minutes to your scan time. The only non-routine measurements will be the research ultrasound data.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of the study is measured at 1 day, focusing on the feasibility of the imaging method.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07270237

A Study of Multiparametric Ultrasound Imaging Methods

Recruiting
NAAges 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~85 participants
Updated 2025-12-12 on ClinicalTrials.gov
What's tested:Multiparametric ultrasound (mpUS) imaging

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
investigate the feasibility of mpEUS imaging
Measured over 1 day

Conditions

Pancreatic Cancer
Thyroid Nodule

Explore related trials

Pancreatic CarcinomaThyroid Gland Nodule

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Mark T Burgess, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Mark T Burgess, PhD
[email protected]
646-608-8284
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer:
10 years younger than the earliest pancreatic cancer diagnosis in the family
Be at least 50 years old
Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)
Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)
Not pregnant and not Nursing
Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)
Must agree to be contacted for follow-up
Must satisfy at least one of the following 4 criteria:
Patients with pancreatic ductal adenocarcinoma
Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care
Not pregnant and not nursing
Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care
Not pregnant and not nursing
No known cancer diagnosis or thyroid nodules
Age ≥ 18
Able to understand and give informed consent
Not pregnant and not nursing

Exclusion

Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
Under 18 years of age
Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
Under 18 years of age

What this trial measures

  • investigate the feasibility of mpEUS imaging1 day

    the feasibility rate will be estimated and reported using the corresponding sample proportion, along with exact binomial 95% confidence intervals. The mpEUS technique will be considered feasible if it is able to visualize/quantify parameters in at least 21 patients out of the 30 patients.